In particular, mutation occurring in the cyclin-dependent kinase inhibitor 2A (CDKN2A) and cyclin-dependent kinase 4 (CDK4) genes are the most frequent genetic abnormalities associated with melanoma risk [22,24]. This evidence concerns the gene CDK4 and melanoma.